Heat Shock Protein Vaccine Trial for Glioblastoma Multiforme

1. VACCINE TRIAL FOR GBM Heat Shock Protein Vaccine Trial for Glioblastoma Multiforme A clinical trial using heat shock protein vaccine (HSPPC-96) for patients with newly diagnosed glioblastoma multiforme.  Cancer immunotherapy has emerged as an important new treatment modality, and HSPPC-96 represents a novel approach to active, specific immunotherapy.  The preliminary results using HSPPC-96 have been promising, nearly doubling life expectancy for this patient population.  This vaccine trial supports the concept of active, tumor and patient specific immunization with autologous, tumor-derived heat-shock protein-peptide complex.   The University of Miami joins an exclusive multi-center group to complete phase II of the study. (only 9 other Medical Centers in the country are involved) . UM is the only center to offer this treatment in the state of Florida. For questions and referrals, please contact the site’s Principle Investigator: Ricardo Jorge Komotar, M.D. Assistant Professor of Neurological Surgery University of Miami School of Medicine Director of Surgical Neurooncology University of Miami Hospital Co-Director of Surgical Neurooncology Sylvester Comprehensive Cancer Center University of Miami Health Clinics 305.243.2427  rkomotar@med.miami.edu